

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

溫州康寧醫院

al Co., L

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the three months (the third quarter) from July 1, 2024 to September 30, 2024 with comparative figures of the same period in 2023

	Three months from July 1 to September 30, 2024	2023	Year- on-year changes
Inpatients			
Number of inpatient bed-days	986,185	926,084	6.5%
Average inpatient spending per bed-day on treatment and general healthcare services (<i>RMB</i>)	320	327	-2.1%
Average inpatient spending per bed-day on pharmaceutical sales (<i>RMB</i>)	48	48	0.0%
Total average inpatient spending per bed-day (<i>RMB</i>)⁽¹⁾	<u>369</u>	<u>375</u>	<u>-1.6%</u>
Outpatients			
Number of outpatient visits	126,201	128,070	-1.5%
Average outpatient spending per visit on treatment and general healthcare services (<i>RMB</i>)	125	137	-8.8%
Average outpatient spending per visit on pharmaceutical sales (<i>RMB</i>)	290	296	-2.0%
Total average outpatient spending per visit (<i>RMB</i>)	<u>415</u>	<u>433</u>	<u>4.2%</u>

Note

- The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data and indicators may be different from those disclosed in relevant periodical reports. The operating data and indicators disclosed in relevant periodical reports shall prevail if there is any discrepancy.

Shareholders and potential investors of the Company are reminded to rationally deal with